- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03283254
PREPP: Preventing Postpartum Depression (PREPP)
February 15, 2024 updated by: Catherine Monk, Columbia University
Preventing Postpartum Depression: A Dyadic Approach Adjunctive to Obstetric Care
The primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or severity of postpartum maternal depression and (2) improve the quality of the mother-infant interaction and subsequent child development.
Specifically, the study team will investigate: (1) the effectiveness of the intervention compared to usual care; (2) if the effects of the intervention can be detected in the assessments of the quality of mother-infant interaction; (3) if there are prenatal and/or postnatal biomarkers that can help identify infants whose behavior is more likely to play a role in their mothers' depression; (4) if these markers differentiate which infants will be most responsive to the intervention(s); and (5), if assessments of brain function at birth and at 4-6 weeks of age provide biological nodal points for identifying the effects of the intervention on infant brain development.
Participants will be recruited during their 2nd trimester, and will be randomly separated into one of two groups: a group that receives coaching in parenting techniques (4 in-person coaching sessions and 1 phone session) or one that receives treatment as usual.
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
Of the nearly 4 million mothers delivering live births each year in the United States, approximately 560,000 - or 14% - will develop major or minor depression within the first four months postpartum, when the rate peaks.
This number dwarfs prevalence rates for gestational diabetes (2-5%) and is comparable to preterm birth (11.4%).
Postpartum depression (PPD) has substantial consequences: poorer maternal quality of life, significant emotional suffering, and suicide risk.
PPD predicts diminished mother-infant bonding, and poor outcomes in social-emotional and, in some groups, cognitive development.
PPD is undertreated in part because women are reluctant to seek treatment due to the stigma associated with mental health care, logistical barriers to at-tending added health care appointments, and disinclination to take medications while breastfeeding.
Of preventive interventions, few embed services in obstetrical care or leverage the unique mother-infant dyadic orientation of the childbearing period.
The investigators developed a novel intervention based on the conceptualization of maternal depression as a potential disorder of the mother-infant dyad, and one that can be approached through psychological and behavioral changes in the mother - commencing before birth - that affect her and the child.
PREPP (Practical Resources for Effective Postpartum Parenting) enrolls distressed pregnant women at risk for PPD, spans late pregnancy to the 6 week postpartum check up, comprises four in-person 'coaching' sessions adjunctive to obstetrical (OB) prenatal and postnatal appointments, one phone session, and imparts (a) mindfulness and self-reflection skills, (b) parenting skills, and (c) psycho-education.
Study Type
Interventional
Enrollment (Actual)
216
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York State Psychiatric Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy pregnant women between 18-45 years old (based on self report)
- A score of ≥21 on the Predictive Index of Postnatal Depression (PIPD), indicating risk for developing postpartum depression
- A healthy, singleton pregnancy (based on self report)
- English speaking (based on self report)
- Receiving standard prenatal care (based on self report)
Exclusion Criteria:
- Multi-fetal pregnancy (based on self-report)
- Smoking, illicit drug use, or alcohol use during pregnancy (based on self-report)
- Acute medical illness or significant pregnancy complication (based on self-report)
- Currently in weekly, individual psychotherapy, including psychopharmacology (based on self report)
- Psychotic d/o; Bipolar I; Major Depressive d/o (based on M.I.N.I.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Practical Resources for Effective Postpartum (PREPP)
A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.
|
A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting).
PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.'
The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.
Other Names:
|
Active Comparator: Enhanced Treatment as Usual
Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring
|
Psychoeducation, Clinical Assessment, Potential Referral: Participants receive "usual care" along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum.
At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score on the Edinburgh Postnatal Depression Scale (EPDS)
Time Frame: Through the 4th Month Postpartum
|
Maternal mood: Postpartum Depression Symptoms will be measured by Edinburgh Postnatal Depression Scale (EPDS).
The EPDS is a 10-item questionnaire that was developed to identify women who have postpartum depression.
Items of the scale correspond to various clinical depression symptoms, such as guilt feeling, sleep disturbance, low energy, anhedonia, and suicidal ideation.
Overall assessment is done by total score, which is determined by adding together the scores for each of the 10 items.
Scores range from 0 to 30, with higher scores indicate more depressive symptoms (worse outcome).
|
Through the 4th Month Postpartum
|
Score on the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Through the 4th Month Postpartum
|
Maternal perception of sleep quality: The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval.
A total of 19 individual items generate 7 "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.
Scores range from 0 to 21, where lower scores indicate a healthier sleep quality (better outcome).
|
Through the 4th Month Postpartum
|
Score on HRSD-24
Time Frame: Through the 4th Month Postpartum
|
The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), sometimes also abbreviated as HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
The patient is rated by a clinician on 24 items scored either on a 5-point Likert-type scale.
Scores range from 0 to 15 with a lower score indicating a better outcome.
|
Through the 4th Month Postpartum
|
Score on the PHQ-9
Time Frame: Through the 4th Month Postpartum
|
The nine-item Patient Health Questionnaire (PHQ-9) is a depressive symptom scale and diagnostic tool introduced in 2001 to screen adult patients in primary care settings.
The instrument assesses for the presence and severity of depressive symptoms and a possible depressive disorder.
It is scored by simply adding up the individual items' scores.
Scores range from 0 to 27 with a lower score indicating a better outcome.
|
Through the 4th Month Postpartum
|
Hamilton Anxiety Scale (HRSA)
Time Frame: Through the 4th Month Postpartum
|
The scale consists of 14 items designed to assess the severity of a patient's anxiety.
Each of the 14 items contains a number of symptoms, and each group of symptoms is rated on a scale of zero to four, with four being the most severe (worse outcome).
All of these scores are used to compute an overarching score that indicates a person's anxiety severity.
|
Through the 4th Month Postpartum
|
Sleep Efficiency (SEact)
Time Frame: Through the 4th Month Postpartum
|
Maternal sleep: ActiGraphy data will be analyzed first and the derived aggregated measures will be used in the model with the self-reported sleep measures.
|
Through the 4th Month Postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score on Brief Infant Sleep Questionnaire (BISQ) (baby)
Time Frame: Through the 4th Month Postpartum
|
The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over prior one week that includes domains such as nocturnal sleep duration, night wakings, method of falling asleep.Scores on each subscale and the total score are scaled from 0 to 100, with higher scores indicating a better outcome.
|
Through the 4th Month Postpartum
|
Cry Behavior (baby)
Time Frame: Through the 4th Month Postpartum
|
Cry behavior will be measured by The Baby Day Diary, which is a 24-hour diary of infant and parental behavior for days.
The number of hours for the crying behavior is averaged over a span of 4 days.
Possible scores range from 0 hours to 24 hours (worse outcome).
|
Through the 4th Month Postpartum
|
Sleep Behavior (baby)
Time Frame: Through the 4th Month Postpartum
|
Sleep behavior will be measured by The Baby Day Diary, which is a 24-hour diary of infant and parental behavior for days.The number of hours of sleep is averaged over a span of 4 days.
Possible scores range from 0 hours to 24 hours (better outcome).
|
Through the 4th Month Postpartum
|
Total Sleep Time (TSTact) (mother)
Time Frame: Through the 4th Month Postpartum
|
Maternal sleep: ActiGraphy data will be analyzed first and the derived aggregated measures will be used in the model with the self-reported sleep measures.
|
Through the 4th Month Postpartum
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Number of Sleep Hours reported on the Self-Reported Sleep Log (mother)
Time Frame: Through the 4th Month Postpartum
|
Self-reported sleep behaviors (including bedtime, time to fall asleep, wake time, etc.) recorded on the days/nights that the actigraphy data is collected.
This would be averaged over a span of 7 days.
|
Through the 4th Month Postpartum
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Elizabeth Werner, PhD, Columbia University
- Principal Investigator: Catherine Monk, PhD, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 12, 2018
Primary Completion (Estimated)
February 28, 2024
Study Completion (Estimated)
February 28, 2024
Study Registration Dates
First Submitted
August 14, 2017
First Submitted That Met QC Criteria
September 12, 2017
First Posted (Actual)
September 14, 2017
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 15, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7428
- R01HD092062 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified data may be made available to other researchers.
IPD Sharing Time Frame
After the completion of the study
IPD Sharing Access Criteria
Permission of the PI
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Depression (PPD)
-
Marinus PharmaceuticalsCompletedBehavioral Symptoms | Depressive Disorder | Depression | Mood Disorders | Pregnancy Complications | Depression, Postpartum | Mental Disorder | Postpartum Disorder | PPD | Postpartum BluesUnited States
-
Marinus PharmaceuticalsCompletedBehavioral Symptoms | Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Pregnancy Complications | Depression, Postpartum | Puerperal Disorders | Postpartum | PPDUnited States
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingPeripartum Depression (PPD)France
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Women's Health Research Institute...CompletedPostpartum Depression | Perinatal Disorder | Postpartum Disorder | Perinatal Depression | Postpartum Anxiety | Postnatal DepressionCanada
-
University of CoimbraEnrolling by invitationPostPartum DepressionPortugal
-
University of MinnesotaNational Institute of Mental Health (NIMH)Completed
-
Sage TherapeuticsCompletedSevere Postpartum DepressionUnited States
-
Women's College HospitalCanadian Institutes of Health Research (CIHR); Michael Garron HospitalCompletedPostpartum Depression | Postpartum Anxiety | Postpartum Blues | Postpartum Mood DisorderCanada
-
Gazi UniversityCompletedPostpartum Depression | Postpartum AdaptationTurkey
Clinical Trials on Practical Resources for Effective Postpartum Parenting (PREPP)
-
New York State Psychiatric InstituteThe Robin Hood FoundationCompletedPostpartum Depression | Infant Development | Rhythm; SleepUnited States
-
Albert Einstein College of MedicineHealth Resources and Services Administration (HRSA); The New SchoolCompletedDomestic Violence | Child MaltreatmentUnited States